Centre for Human Drug Research is a foundation established under Dutch Law. Its articles of association determine that the foundation is governed by a two tier board system: the Management Board is responsible for the daily executive management whilst the Supervisory Board monitors executive management.
The Management Board is entrusted with the daily management of the foundation and responsible for designing and implementing policy. Tasks and responsibilities of the Management Board are set out in the Management Statute of CHDR in more detail. Business decisions with a significant financial or organizational impact are subject to prior approval of the Supervisory Board.
Members of the Management Board are appointed, monitored, evaluated and dismissed by the Supervisory Board.
The Management Board is currently formed by:
- Koos Burggraaf, Chief Executive Officer
- Geert Jan Groeneveld, Chief Scientific Officer/Chief Medical Officer
- Pierre Peeters, Chief Operations Officer
The Management Team is formed by senior staff of the company. The Management Team Members are collectively and individually responsible for the daily management (of a part) of the organization delegated to them by the Management Board.
The Management Team is chaired by the Management Board and current members are:
- Joop van Gerven, Research Director
- Gabriel Jacobs, Research Director
- Matthijs Moerland, Research Director
- Robert Rissmann, Research Director
- Bart Mooy, Financial Director
The Supervisory Board is charged with supervising the policy of the Management Board and the general affairs of the foundation as well as advising the Management Board. Tasks and responsibilities are defined in the Regulations for the Supervisory Board. The Supervisory Board meets in principle 4 times per year.
Members of the Supervisory Board are appointed by Leiden University by recommendation of the Supervisory Board.
The Supervisory Board has installed 3 committees:
- Audit committee: monitors CHDRs financial reporting and control systems;
- Remuneration committee: reviews the performance of the Management Board and draws up proposals for the remuneration of the Management Board and Supervisory Board;
- Committee Quality and Scientific Integrity: reviews CHDRs measures and policies on quality and scientific integrity.
The tasks and responsibilities of each committee are set forth in separate regulations for each committee.
The Supervisory Board is currently formed by
- Bernard Cohen
- Frans Eelkman Rooda, chairman
- Jan Hendrik Egberts
- Peter Leijh, vice chairman
- Marcel Levi
Resume of the members can befound here.
Certain decisions of the Management Board and the Supervisory Board are subject to a final advice or decision by the Employee Council. This is a legal requirement imposed by the Employee Council Law (Wet op de Ondernemingsraad) of the Netherlands.
In order to maintain a sound financial position CHDR has implemented the following:
- CHDR Treasury Regulations which provides principles and guidelines regarding cash flow management, financing and risk management
- CHDR Investment Statute (currently in draft) which provides guidelines that ensure that investment decisions are based on sound considerations and thorough research
Scientific Advisory Board
The Scientific Advisory Board (SAB) advises CHDR on the scientific quality of CHDR’s projects and on the general scientific strategy. In addition, the SAB serves an important role in the education and proficiency of CHDR's PhD-candidates, trainees and interns.
SAB members are nominated by CHDR's CEO and Research Directors. The SAB members are external members. The composition of the SAB is chosen to reflect the expertise necessary to cover the activities and specific interest of CHDR. The SAB consists of at least five external members, elected for their expertise in various areas of pharmacology and medicine.
The role of the SAB is set out in a standard operating procedure “Scientific Review”.
List of members of the SAB, can be found here.